RSS Feed ALL http://www.jingshen2.com/rss-feed/all.rss Johnson & Johnson en-us Fri, 09 Aug 2019 20:53:33 GMT 22 23 0 1 2 3 4 5 60 Janssen Announces U.S. FDA Accelerated Approval for SIRTURO? (bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant Tuberculosis http://www.jingshen2.com/janssen-announces-u-s-fda-accelerated-approval-for-sirturo-bedaquiline-as-part-of-combination-therapy-to-treat-adolescents-with-pulmonary-multidrug-resistant-tuberculosis Fri, 09 Aug 2019 20:53:33 GMT http://www.jingshen2.com/janssen-announces-u-s-fda-accelerated-approval-for-sirturo-bedaquiline-as-part-of-combination-therapy-to-treat-adolescents-with-pulmonary-multidrug-resistant-tuberculosis Johnson & Johnson to Participate in Barclays Global Consumer Staples Conference http://www.jingshen2.com/johnson-johnson-to-participate-in-2019-barclays-global-consumer-staples-conference Thu, 08 Aug 2019 18:47:59 GMT http://www.jingshen2.com/johnson-johnson-to-participate-in-2019-barclays-global-consumer-staples-conference Johnson & Johnson to Participate in the Wells Fargo Securities 2019 Healthcare Conference http://www.jingshen2.com/johnson-johnson-to-participate-in-the-wells-fargo-securities-2019-healthcare-conference Thu, 08 Aug 2019 18:41:39 GMT http://www.jingshen2.com/johnson-johnson-to-participate-in-the-wells-fargo-securities-2019-healthcare-conference Janssen reports positive top-line Phase 3 results for ponesimod in adults with relapsing multiple sclerosis http://www.jingshen2.com/janssen-reports-positive-top-line-phase-3-results-for-ponesimod-in-adults-with-relapsing-multiple-sclerosis Thu, 25 Jul 2019 20:28:27 GMT http://www.jingshen2.com/janssen-reports-positive-top-line-phase-3-results-for-ponesimod-in-adults-with-relapsing-multiple-sclerosis Johnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine Regimen http://www.jingshen2.com/johnson-johnson-announces-new-clinical-data-on-mosaic-based-hiv-preventive-vaccine-regimen Tue, 23 Jul 2019 15:00:24 GMT http://www.jingshen2.com/johnson-johnson-announces-new-clinical-data-on-mosaic-based-hiv-preventive-vaccine-regimen Johnson & Johnson Establishes International Consortium to Advance Pioneering Science in the Fight to End Tuberculosis http://www.jingshen2.com/johnson-johnson-establishes-international-consortium-to-advance-pioneering-science-in-the-fight-to-end-tuberculosis Tue, 23 Jul 2019 12:28:41 GMT http://www.jingshen2.com/johnson-johnson-establishes-international-consortium-to-advance-pioneering-science-in-the-fight-to-end-tuberculosis Johnson & Johnson Reports 2019 Second-Quarter Results: http://www.jingshen2.com/johnson-johnson-reports-2019-second-quarter-results Tue, 16 Jul 2019 10:40:37 GMT http://www.jingshen2.com/johnson-johnson-reports-2019-second-quarter-results Johnson & Johnson Extends Long-Standing Donation Program to Support Global Effort to Tackle Intestinal Worms http://www.jingshen2.com/johnson-johnson-extends-long-standing-donation-program-to-support-global-effort-to-tackle-intestinal-worms Tue, 16 Jul 2019 07:00:32 GMT http://www.jingshen2.com/johnson-johnson-extends-long-standing-donation-program-to-support-global-effort-to-tackle-intestinal-worms Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2019 http://www.jingshen2.com/johnson-johnson-announces-quarterly-dividend-for-third-quarter-2019 Mon, 15 Jul 2019 15:01:27 GMT http://www.jingshen2.com/johnson-johnson-announces-quarterly-dividend-for-third-quarter-2019 Johnson & Johnson Announces New Public-Private Partnership to Support First Phase 3 Efficacy Study of Janssen’s Investigational Prophylactic HIV Vaccine http://www.jingshen2.com/johnson-johnson-announces-new-public-private-partnership-to-support-first-phase-3-efficacy-study-of-janssens-investigational-prophylactic-hiv-vaccine Mon, 15 Jul 2019 14:10:00 GMT http://www.jingshen2.com/johnson-johnson-announces-new-public-private-partnership-to-support-first-phase-3-efficacy-study-of-janssens-investigational-prophylactic-hiv-vaccine Janssen Submits Application to U.S. FDA Seeking Approval of New DARZALEX? (daratumumab) Subcutaneous Formulation http://www.jingshen2.com/janssen-submits-application-to-u-s-fda-seeking-approval-of-new-darzalex-daratumumab-subcutaneous-formulation Fri, 12 Jul 2019 16:42:03 GMT http://www.jingshen2.com/janssen-submits-application-to-u-s-fda-seeking-approval-of-new-darzalex-daratumumab-subcutaneous-formulation XARELTO? (rivaroxaban) Helps Protect Pediatric Patients from Blood Clots in Late-Breaking Phase 3 EINSTEIN-Jr Study http://www.jingshen2.com/xarelto-rivaroxaban-helps-protect-pediatric-patients-from-blood-clots-in-late-breaking-phase-3-einstein-jr-study Mon, 08 Jul 2019 13:48:30 GMT http://www.jingshen2.com/xarelto-rivaroxaban-helps-protect-pediatric-patients-from-blood-clots-in-late-breaking-phase-3-einstein-jr-study Janssen Announces U.S. FDA Approval of DARZALEX? (daratumumab) in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients with Multiple Myeloma Who Are Transplant Ineligible http://www.jingshen2.com/janssen-announces-u-s-fda-approval-of-darzalex-daratumumab-in-combination-with-lenalidomide-and-dexamethasone-for-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible Thu, 27 Jun 2019 18:50:30 GMT http://www.jingshen2.com/janssen-announces-u-s-fda-approval-of-darzalex-daratumumab-in-combination-with-lenalidomide-and-dexamethasone-for-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible Janssen Announces Collaboration with University of California, Berkeley and University of California, San Francisco to Expand Data Science Research in Healthcare http://www.jingshen2.com/janssen-announces-collaboration-with-university-of-california-berkeley-and-university-of-california-san-francisco-to-expand-data-science-research-in-healthcare Fri, 21 Jun 2019 17:01:27 GMT http://www.jingshen2.com/janssen-announces-collaboration-with-university-of-california-berkeley-and-university-of-california-san-francisco-to-expand-data-science-research-in-healthcare Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results http://www.jingshen2.com/johnson-johnson-to-host-investor-conference-call-on-second-quarter-results-2019 Tue, 18 Jun 2019 11:47:47 GMT http://www.jingshen2.com/johnson-johnson-to-host-investor-conference-call-on-second-quarter-results-2019 Janssen reports top-line Phase 3 results for TREMFYA? (guselkumab) in adults with active psoriatic arthritis http://www.jingshen2.com/janssen-reports-top-line-phase-3-results-for-tremfya-guselkumab-in-adults-with-active-psoriatic-arthritis Fri, 14 Jun 2019 14:34:03 GMT http://www.jingshen2.com/janssen-reports-top-line-phase-3-results-for-tremfya-guselkumab-in-adults-with-active-psoriatic-arthritis INVOKANA? (canagliflozin) Significantly Reduced Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in New CREDENCE Analysis http://www.jingshen2.com/invokana-canagliflozin-significantly-reduced-major-cardiovascular-events-and-kidney-failure-in-patients-with-type-2-diabetes-and-chronic-kidney-disease-in-new-credence-analysis Tue, 11 Jun 2019 17:12:06 GMT http://www.jingshen2.com/invokana-canagliflozin-significantly-reduced-major-cardiovascular-events-and-kidney-failure-in-patients-with-type-2-diabetes-and-chronic-kidney-disease-in-new-credence-analysis Johnson & Johnson Releases 2018 Health for Humanity Report http://www.jingshen2.com/johnson-johnson-releases-2018-health-for-humanity-report Wed, 05 Jun 2019 13:39:46 GMT http://www.jingshen2.com/johnson-johnson-releases-2018-health-for-humanity-report IMBRUVICA? (ibrutinib) Long-Term Data from Two Pivotal Phase 3 Studies at ASCO and EHA Demonstrate Sustained Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL) http://www.jingshen2.com/imbruvica-ibrutinib-long-term-data-from-two-pivotal-phase-3-studies-at-asco-and-eha-demonstrate-sustained-efficacy-and-safety-in-patients-with-chronic-lymphocytic-leukemia-cll Mon, 03 Jun 2019 14:25:37 GMT http://www.jingshen2.com/imbruvica-ibrutinib-long-term-data-from-two-pivotal-phase-3-studies-at-asco-and-eha-demonstrate-sustained-efficacy-and-safety-in-patients-with-chronic-lymphocytic-leukemia-cll DARZALEX? (daratumumab) Investigational Study Shows Increased Depth of Response and Longer Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Eligible for a Transplant http://www.jingshen2.com/darzalex-daratumumab-investigational-study-shows-increased-depth-of-response-and-longer-progression-free-survival-in-patients-with-newly-diagnosed-multiple-myeloma-who-are-eligible-for-a-transplant Mon, 03 Jun 2019 14:21:39 GMT http://www.jingshen2.com/darzalex-daratumumab-investigational-study-shows-increased-depth-of-response-and-longer-progression-free-survival-in-patients-with-newly-diagnosed-multiple-myeloma-who-are-eligible-for-a-transplant Phase 3 COLUMBA Study Investigating a Subcutaneous Formulation of DARZALEX? (daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma http://www.jingshen2.com/phase-3-columba-study-investigating-a-subcutaneous-formulation-of-darzalex-daratumumab-showed-non-inferiority-to-intravenous-administration-in-patients-with-relapsed-refractory-multiple-myeloma Mon, 03 Jun 2019 14:17:31 GMT http://www.jingshen2.com/phase-3-columba-study-investigating-a-subcutaneous-formulation-of-darzalex-daratumumab-showed-non-inferiority-to-intravenous-administration-in-patients-with-relapsed-refractory-multiple-myeloma ERLEADA? (apalutamide) Significantly Improved Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) http://www.jingshen2.com/erleada-apalutamide-significantly-improved-overall-survival-os-and-radiographic-progression-free-survival-rpfs-in-patients-with-metastatic-castration-sensitive-prostate-cancer-mcspc Fri, 31 May 2019 22:32:16 GMT http://www.jingshen2.com/erleada-apalutamide-significantly-improved-overall-survival-os-and-radiographic-progression-free-survival-rpfs-in-patients-with-metastatic-castration-sensitive-prostate-cancer-mcspc DARZALEX? (daratumumab) Phase 3 MAIA Study Results Published in The New England Journal of Medicine Show Combination Therapy Increases Progression-Free Survival in Newly Diagnosed Patients with Multiple Myeloma Who are Transplant Ineligible http://www.jingshen2.com/darzalex-daratumumab-phase-3-maia-study-results-published-in-the-new-england-journal-of-medicine-show-combination-therapy-increases-progression-free-survival-in-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible Wed, 29 May 2019 22:23:55 GMT http://www.jingshen2.com/darzalex-daratumumab-phase-3-maia-study-results-published-in-the-new-england-journal-of-medicine-show-combination-therapy-increases-progression-free-survival-in-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible Johnson & Johnson Announces Full Enrollment in Proof-of-Concept Efficacy Study of Janssen’s Investigational HIV Preventive Vaccine http://www.jingshen2.com/johnson-johnson-announces-full-enrollment-in-proof-of-concept-efficacy-study-of-janssens-investigational-hiv-preventive-vaccine Wed, 29 May 2019 10:01:26 GMT http://www.jingshen2.com/johnson-johnson-announces-full-enrollment-in-proof-of-concept-efficacy-study-of-janssens-investigational-hiv-preventive-vaccine New Data Highlights the Value of SPRAVATO? (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)[1] http://www.jingshen2.com/new-data-highlights-the-value-of-spravato-esketamine-ciii-nasal-spray-the-first-new-antidepressant-in-decades-that-works-differently-for-adults-with-treatment-resistant-depression-trdi Wed, 22 May 2019 13:55:01 GMT http://www.jingshen2.com/new-data-highlights-the-value-of-spravato-esketamine-ciii-nasal-spray-the-first-new-antidepressant-in-decades-that-works-differently-for-adults-with-treatment-resistant-depression-trdi 免费黄片